At a glance
- Originator Eli Lilly and Company
- Class Oligopeptides; Small molecules; Thrombolytics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ischaemic heart disorders; Thrombosis
Most Recent Events
- 06 Nov 1997 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
- 06 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
- 24 Oct 1994 Preclinical development for Ischaemic heart disorders in USA (Unknown route)